^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG CLASS:

CD20-targeted CAR-T immunotherapy

Phase 1/2
Medical College of Wisconsin
Recruiting
Last update posted :
02/18/2025
Initiation :
05/18/2020
Primary completion :
06/30/2026
Completion :
06/01/2028
BCL2
|
CAR-20/19-T Cells
Phase 1
Janssen Research & Development, LLC
Recruiting
Last update posted :
02/06/2025
Initiation :
08/12/2022
Primary completion :
05/29/2026
Completion :
12/29/2028
CD20
|
CD20 positive
|
prizloncabtagene autoleucel (JNJ-4496)
Phase 1/2
Regeneron Pharmaceuticals
Active, not recruiting
Last update posted :
02/03/2025
Initiation :
01/24/2022
Primary completion :
08/31/2025
Completion :
08/31/2025
BCL2 • BCL6
|
BCL6 rearrangement • BCL2 rearrangement
|
bbT369
Phase 1
Sumithira Vasu
Recruiting
Last update posted :
02/03/2025
Initiation :
06/30/2022
Primary completion :
04/30/2025
Completion :
07/31/2026
CD20 • CD19 • CD22
|
CD20 positive
|
cyclophosphamide • fludarabine IV • Anti-CD19/CD20/CD22 CAR T-Cells
Phase 1/2
ImmPACT Bio
Recruiting
Last update posted :
01/14/2025
Initiation :
05/09/2023
Primary completion :
06/01/2025
Completion :
12/01/2029
BCL2 • BCL6
|
BCL6 rearrangement • BCL2 rearrangement
|
rondecabtagene autoleucel (IMPT-314)
Phase 1
Shanghai First Song Biotechnology Co., LTD
Recruiting
Last update posted :
09/19/2024
Initiation :
08/24/2023
Primary completion :
09/01/2025
Completion :
09/01/2026
TNFRSF8
|
cyclophosphamide • fludarabine IV
Phase 1/2
Fred Hutchinson Cancer Center
Active, not recruiting
Last update posted :
06/12/2024
Initiation :
12/05/2017
Primary completion :
03/29/2024
Completion :
11/16/2037
BCL2
|
CD20 expression
|
cyclophosphamide • fludarabine IV • MB-106
Phase 1
Poseida Therapeutics, Inc.
Recruiting
Last update posted :
06/03/2024
Initiation :
04/16/2024
Primary completion :
03/01/2029
Completion :
03/01/2041
CD20 • CD5 • FCER2
|
CD20 positive
|
RG6540 • rimiducid (AP1903)
Phase 1
Shanghai Tongji Hospital, Tongji University Sch...
Completed
Last update posted :
05/28/2024
Initiation :
08/20/2019
Primary completion :
06/20/2022
Completion :
06/20/2022
CD20
|
JNJ-9530
Phase 1
Institute of Hematology & Blood Diseases Hospit...
Active, not recruiting
Last update posted :
05/14/2024
Initiation :
03/14/2022
Primary completion :
07/01/2024
Completion :
07/01/2026
CD20 • CD22
|
CD19 expression
|
cyclophosphamide • LCAR-AIO
Phase 1/2
Uppsala University
Recruiting
Last update posted :
05/09/2024
Initiation :
05/01/2024
Primary completion :
12/30/2027
Completion :
12/30/2027
CD20
|
cyclophosphamide • fludarabine IV • ELC-301
Phase 1/2
Miltenyi Biomedicine GmbH
Active, not recruiting
Last update posted :
04/30/2024
Initiation :
02/25/2019
Primary completion :
12/17/2020
Completion :
12/31/2025
BCL2 • BCL6
|
CD19 expression • BCL6 rearrangement • BCL2 rearrangement
|
zamtocabtagene autoleucel (MB-CART2019.1)
Phase 2
Miltenyi Biomedicine GmbH
Recruiting
Last update posted :
04/30/2024
Initiation :
08/18/2021
Primary completion :
12/31/2024
Completion :
07/31/2027
BCL2 • CD19 • BCL6
|
CD19 expression • BCL6 rearrangement • BCL2 rearrangement
|
gemcitabine • Rituxan (rituximab) • oxaliplatin • bendamustine • Polivy (polatuzumab vedotin-piiq) • zamtocabtagene autoleucel (MB-CART2019.1)
Phase 1/2
Miltenyi Biomedicine GmbH
Active, not recruiting
Last update posted :
04/23/2024
Initiation :
09/25/2018
Primary completion :
09/30/2024
Completion :
09/30/2024
CD20
|
MB-CART20.1
Phase 1
Ruijin Hospital
Recruiting
Last update posted :
04/15/2024
Initiation :
12/25/2021
Primary completion :
08/31/2024
Completion :
05/31/2026
CD20
|
CD20 expression
|
LY007
Phase 1/2
Cellectis S.A.
Recruiting
Last update posted :
03/01/2024
Initiation :
11/01/2022
Primary completion :
11/01/2027
Completion :
11/01/2027
BCL2 • BCL6 • CD22
|
CD20 positive • BCL6 rearrangement • BCL2 rearrangement
|
Campath (alemtuzumab) • UCART20x22
Phase 1
Shanghai Longyao Biotechnology Inc., Ltd.
Recruiting
Last update posted :
02/28/2024
Initiation :
12/25/2021
Primary completion :
08/31/2024
Completion :
05/31/2026
CD20
|
CD20 expression
|
LY007
Phase 1/2
Han weidong
Recruiting
Last update posted :
02/07/2024
Initiation :
12/15/2020
Primary completion :
12/30/2024
Completion :
12/30/2025
BCL2 • CCND1 • BCL6
|
Chr t(11;14) • CCND1 overexpression • BCL6 rearrangement • Chr t(11;14)(q13;q32) • BCL2 rearrangement • CD20 negative
|
cyclophosphamide • decitabine • fludarabine IV
Phase 1/2
Mustang Bio
Recruiting
Last update posted :
12/20/2023
Initiation :
05/24/2022
Primary completion :
09/01/2026
Completion :
09/01/2026
BCL2 • CD20 • BCL6
|
CD19 positive • CD20 expression • BCL6 rearrangement • BCL2 rearrangement
|
MB-106
Phase 1
Jonsson Comprehensive Cancer Center
Recruiting
Last update posted :
10/06/2023
Initiation :
10/04/2019
Primary completion :
08/01/2024
Completion :
08/01/2025
CD20 • CD8 • CD4
|
CD19 expression
|
cyclophosphamide • fludarabine IV • Actemra IV (tocilizumab) • cyclophosphamide intravenous
Phase 1/2
Shanghai Unicar-Therapy Bio-medicine Technology...
Recruiting
Last update posted :
09/21/2023
Initiation :
03/28/2023
Primary completion :
12/31/2024
Completion :
12/31/2026
IL6
|
CD20 positive • CD20 negative
|
cyclophosphamide • U16
Phase 1
Medical College of Wisconsin
Active, not recruiting
Last update posted :
08/23/2023
Initiation :
06/30/2022
Primary completion :
02/01/2025
Completion :
02/01/2026
BCL2
|
CAR20.19.22 T
Phase 1
Qiu Lugui
Recruiting
Last update posted :
08/03/2023
Initiation :
03/14/2022
Primary completion :
06/30/2024
Completion :
06/30/2026
CD20 • CD22
|
CD19 expression
|
cyclophosphamide • LCAR-AIO
Phase 1
Institute of Hematology & Blood Diseases Hospital
Completed
Last update posted :
07/19/2023
Initiation :
09/29/2019
Primary completion :
02/08/2023
Completion :
02/08/2023
CD20
|
CD20 positive
|
JNJ-9530
Phase 1b/2
Cellular Biomedicine Group Ltd.
Recruiting
Last update posted :
04/06/2023
Initiation :
02/22/2023
Primary completion :
03/31/2027
Completion :
03/31/2027
BCL2 • CD20 • CD19 • BCL6
|
CD20 positive • CD20 expression • CD19 expression • BCL6 rearrangement • BCL2 rearrangement
|
prizloncabtagene autoleucel (JNJ-4496)
Phase 1/2
Precision BioSciences, Inc.
Completed
Last update posted :
01/31/2023
Initiation :
03/24/2020
Primary completion :
06/24/2021
Completion :
06/24/2021
CD20
|
cyclophosphamide • fludarabine IV • PBCAR 20A
Phase 1
Hebei Yanda Ludaopei Hospital
Completed
Last update posted :
03/08/2022
Initiation :
03/10/2020
Primary completion :
10/10/2021
Completion :
02/10/2022
CD20 • CD19
|
CD20 positive • CD19 expression
|
cyclophosphamide • fludarabine IV • YTS101
Phase 1
Hebei Yanda Ludaopei Hospital
Completed
Last update posted :
03/08/2022
Initiation :
03/01/2020
Primary completion :
05/10/2021
Completion :
09/10/2021
CD20 • CD19
|
CD20 positive • CD19 expression
|
cyclophosphamide • fludarabine IV • YTS101
Phase 1
Beijing Tsinghua Chang Gung Hospital
Suspended
Last update posted :
02/14/2022
Initiation :
03/10/2022
Primary completion :
03/10/2023
Completion :
06/10/2023
CD20 • CD19
|
CD20 positive • CD19 expression
|
cyclophosphamide • fludarabine IV • YTS101
Phase 1
Peking University
Recruiting
Last update posted :
12/08/2021
Initiation :
07/20/2021
Primary completion :
07/01/2024
Completion :
10/01/2024
BCL2 • BCL6
|
CD20 positive
|
prizloncabtagene autoleucel (JNJ-4496)
Phase 1
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Recruiting
Last update posted :
03/08/2021
Initiation :
04/19/2019
Primary completion :
05/01/2021
Completion :
06/01/2021
CD20
|
CD20 positive
|
CD19/CD20 CAR T-cells
Phase 1/2
Shenzhen Geno-Immune Medical Institute
Recruiting
Last update posted :
11/19/2020
Initiation :
11/18/2020
Primary completion :
11/19/2020
Completion :
12/31/2023
CD276
|
4SCAR-T • GD2, PSMA and CD276 CAR-T
Phase 1/2
Chinese PLA General Hospital
Completed
Last update posted :
09/02/2020
Initiation :
04/01/2017
Primary completion :
05/10/2019
Completion :
01/31/2020
CD20
Phase 1/2
Shenzhen Geno-Immune Medical Institute
Recruiting
Last update posted :
06/12/2020
Initiation :
06/01/2020
Primary completion :
05/31/2023
Completion :
12/31/2023
CD20 • CD38 • CD123 • CD22 • MME • IL3RA
|
4SCAR-T
Phase 1/2
Shenzhen Geno-Immune Medical Institute
Recruiting
Last update posted :
06/12/2020
Initiation :
06/01/2020
Primary completion :
07/31/2023
Completion :
12/31/2023
CD19 • CD79B • CD22 • CD70 • ANPEP
|
CD19 expression
|
multi-CAR-T cell therapy
Phase 1/2
Shenzhen Geno-Immune Medical Institute
Recruiting
Last update posted :
06/12/2020
Initiation :
06/01/2020
Primary completion :
05/31/2023
Completion :
12/31/2023
HER-2
|
HER-2 expression • CD44 expression
|
4SCAR-T
Phase 1
Shanghai Longyao Biotechnology Inc., Ltd.
Recruiting
Last update posted :
11/20/2019
Initiation :
11/22/2019
Primary completion :
11/22/2022
Completion :
11/22/2022
CD20
|
CD20 expression
|
LY007
Phase 1
iCell Gene Therapeutics
Unknown status
Last update posted :
11/12/2019
Initiation :
08/01/2018
Primary completion :
09/30/2020
Completion :
09/30/2020
CD20
|
CD20 expression • CD19 expression
|
CD20-CD19 cCAR T cells
Phase 1/2
Shenzhen Geno-Immune Medical Institute
Recruiting
Last update posted :
09/19/2019
Initiation :
07/15/2019
Primary completion :
07/15/2021
Completion :
12/15/2023
CD20 • CD38 • CRLF2 • CD22 • MME • IL3RA
|
4SCAR-CD22/CD123/CD38/CD10/CD20/TSLPR • 4SCAR-T
Phase 1/2
Southwest Hospital, China
Unknown status
Last update posted :
06/25/2019
Initiation :
03/01/2016
Primary completion :
03/01/2020
Completion :
03/01/2021
CD20
|
CD20 expression
Phase 2
The First Affiliated Hospital of Soochow Univer...
Unknown status
Last update posted :
04/16/2019
Initiation :
06/01/2017
Primary completion :
05/31/2021
Completion :
05/31/2021
CD20 • TNFRSF8 • CD22
|
CAR-T CD19/CD20/CD22/CD30